Value Sense
SLN
Silence Therapeutics plc (SLN)
Last Price$4.3(4.0%)
Market Cap$211.4B
LTM Rule of 40 (EBIT margin)
(401.0%)
5Y avg
(63.6%)
Biotechnology industry median
(288.7%)
Stock quality & Intrinsic value
6/10
(1.0%) overvalued
SLN
is (99.8%) overvalued
learn more -->
50+
undervalued stocks
Start beating the S&P 500

Silence Therapeutics plc Rule of 40 (EBIT margin)

Annual
Quarterly
LTM
Industry median
Company stand-alone
SLN
Healthcare
Crunching data... Almost there!
Dec'04Dec'05Dec'06Dec'07Dec'08Dec'09Dec'10Dec'11Dec'12Dec'13Dec'14Dec'15Dec'16Dec'17Dec'18Dec'19Dec'20Dec'21Dec'22Dec'23
Rule of 40 (EBIT margin)
0.0%
(545.7%)
63.3%
(35.2%)
(398.2%)
(460.4%)
(328.6%)
(904.4%)
(16,220.1%)
(7,782.1%)
(80,933.8%)
0.0%
0.0%
(90,041.7%)
0.0%
0.0%
1,491.2%
(242.4%)
(236.7%)
(150.5%)
SLN
Key metrics and insights to make informed decisions.
View full analysis
Overvalued or undervalued?
Check the intrinsic value for SLN and see if it's the right time to invest.
Dive in

Silence Therapeutics plc (SLN) Rule of 40 (EBIT margin) comparison analysis

General

LTM Rule of 40 (EBIT margin)

OTHER METRICS

Company name

Revenue growth

EPS growth

Net Income margin

Silence Therapeutics plc logo
Silence Therapeutics plcSLN
(401.0%)
45.7%
(6.7%)
(170.5%)
Median Peer Set
20.2%
18.9%
(47.6%)
0.4%
argenx SE logo
argenx SEARGX
110.3%
198.6%
(60.5%)
(24.1%)
United Therapeutics Corporation logo
United Therapeutics CorporationUTHR
71.5%
23.6%
25.7%
41.5%
Novo Nordisk A/S logo
Novo Nordisk A/SNVO
69.3%
24.9%
142.8%
34.8%
Regeneron Pharmaceuticals, Inc. logo
Regeneron Pharmaceuticals, Inc.REGN
36.6%
8.3%
10.4%
31.1%
BeiGene, Ltd. logo
BeiGene, Ltd.BGNE
24.2%
73.7%
(56.5%)
(35.9%)
Incyte Corporation logo
Incyte CorporationINCY
16.2%
14.8%
(94.0%)
0.8%
Alnylam Pharmaceuticals, Inc. logo
Alnylam Pharmaceuticals, Inc.ALNY
15.1%
23.0%
(38.6%)
(12.4%)
Vertex Pharmaceuticals Incorporated logo
Vertex Pharmaceuticals IncorporatedVRTX
9.3%
11.7%
N/A
(4.9%)
BioNTech SE logo
BioNTech SEBNTX
(84.9%)
(77.4%)
(89.7%)
24.4%
Summit Therapeutics Inc. logo
Summit Therapeutics Inc.SMMT
N/A
N/A
(68.7%)
N/A

SLN key stats

USD
GBP
Millions
Billions
Annual
Quarterly
Trailing
Key stats
Income statement
Balance sheet
Cash Flow Statement
Valuation
Ratios
Per share
Per employee
Dividends & Yields
Dec'04Dec'05Dec'06Dec'07Dec'08Dec'09Dec'10Dec'11Dec'12Dec'13Dec'14Dec'15Dec'16Dec'17Dec'18Dec'19Dec'20Dec'21Dec'22Dec'23
Revenue
% growth
0.3
0.0%
0.9
217.9%
3.6
287.2%
8.1
125.8%
4.1
(49.5%)
2.7
(34.1%)
3.7
35.5%
1.1
(69.6%)
0.3
(76.8%)
0.2
(29.1%)
0.0
(86.5%)
0.0
(100.0%)
1.0
0.0%
0.0
(98.0%)
0.0
(100.0%)
0.3
0.0%
7.0
2,158.4%
17.1
142.7%
21.7
26.8%
31.6
45.7%
Cost of Goods Sold (COGS)0.00.00.09.712.47.99.05.45.48.814.610.911.810.213.00.04.810.313.512.8
Gross Profit
% margin
0.3
100.0%
0.9
100.0%
3.6
100.0%
(1.6)
(19.7%)
(8.3)
(203.8%)
(5.2)
(194.4%)
(5.3)
(146.0%)
(4.3)
(384.3%)
(5.1)
(1,972.4%)
(8.7)
(4,727.4%)
(14.6)
(59,126.7%)
(10.9)
0.0%
(10.8)
(1,031.3%)
(10.2)
(49,543.8%)
(13.0)
0.0%
0.3
100.0%
2.2
31.3%
6.8
39.9%
8.2
37.8%
18.7
59.3%
Operating Expenses6.58.011.49.76.16.67.94.29.514.420.014.917.218.627.529.348.269.868.380.4
Research & Development Expenses (R&D)3.13.05.99.712.47.99.05.45.48.814.610.911.810.213.017.025.942.344.054.7
Selling, General & Administrative Expenses (SG&A)3.45.05.610.06.15.07.94.24.15.55.44.15.48.314.512.318.027.524.325.7
Operating Income
% margin
(6.2)
(2,118.2%)
(7.1)
(765.8%)
(7.9)
(219.2%)
(11.6)
(143.0%)
(14.4)
(352.7%)
(11.8)
(438.4%)
(13.4)
(365.9%)
(9.3)
(833.7%)
(41.7)
(16,143.6%)
(14.2)
(7,753.8%)
(20.0)
(80,846.7%)
(14.9)
0.0%
(16.1)
(1,546.2%)
(18.5)
(89,943.8%)
(27.5)
0.0%
(29.0)
(9,317.2%)
(46.0)
(654.3%)
(63.0)
(369.0%)
(60.1)
(277.7%)
(61.7)
(195.5%)
Interest Income0.20.50.61.10.70.10.10.10.00.10.20.32.10.30.10.00.20.00.31.8
Interest Expense0.10.00.00.0(0.1)0.00.10.00.00.00.00.00.00.00.00.20.40.00.10.0
Pre-tax Income(6.1)(6.6)(7.3)(10.5)(13.8)(11.8)(13.6)(9.2)(41.7)(14.1)(19.7)(14.4)(14.1)(4.9)(27.4)(29.2)(46.3)(63.1)(58.6)(62.6)
Income Tax
% effective tax rate
(0.6)
10.6%
(0.1)
1.4%
(0.2)
2.9%
(0.3)
2.6%
(0.7)
4.8%
(0.1)
0.5%
0.2
(1.6%)
(0.1)
0.9%
(0.0)
0.1%
(0.1)
0.8%
(1.5)
7.4%
(4.3)
29.5%
(2.6)
18.5%
(2.8)
57.1%
(2.8)
10.3%
(4.2)
14.4%
(4.5)
9.7%
(8.9)
14.1%
(8.5)
14.5%
(8.8)
14.0%
Net Income
% margin
(5.4)
(1,859.1%)
(6.5)
(704.3%)
(7.0)
(196.5%)
(10.2)
(126.2%)
(13.8)
(336.6%)
(11.7)
(433.6%)
(13.6)
(371.7%)
(9.2)
(826.7%)
(41.7)
(16,125.2%)
(14.1)
(7,694.0%)
(18.3)
(73,920.0%)
(10.2)
0.0%
(11.4)
(1,096.1%)
(2.1)
(10,112.5%)
(24.6)
0.0%
(25.0)
(8,025.4%)
(41.8)
(594.0%)
(54.2)
(317.4%)
(50.1)
(231.4%)
(53.8)
(170.5%)
EPS(34.04)(16.07)(11.11)(13.19)(17.23)(13.03)(7.33)(2.95)(6.51)(0.95)(1.09)(0.47)(0.49)(0.09)(1.05)(1.00)(1.53)(1.83)(1.56)(1.45)
Diluted EPS(34.04)(16.07)(11.11)(13.19)(17.23)(13.03)(7.33)(2.95)(6.51)(0.95)(1.09)(0.47)(0.49)(0.09)(1.05)(1.00)(1.53)(1.83)(1.56)(1.45)
EBITDA
% margin
(5.9)
(2,011.3%)
(6.2)
(671.5%)
(6.6)
(184.2%)
(10.6)
(131.4%)
(13.8)
(336.8%)
(11.1)
(413.1%)
(12.6)
(345.3%)
(8.7)
(780.8%)
(8.4)
(3,255.8%)
(13.7)
(7,500.0%)
(19.4)
(78,633.3%)
(14.7)
0.0%
(15.7)
(1,506.0%)
(4.3)
(20,793.8%)
(26.9)
0.0%
(28.5)
(9,161.9%)
(45.6)
(648.5%)
(62.5)
(365.9%)
(59.2)
(273.6%)
(61.9)
(196.2%)

Discover more Stock Ideas

Undervalued stocks right now

Undervalued stocks right now

Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.

3M Return 32.1%
S&P Outperformance 19.1%
Next 3M Predicted Return 20.3%
Undervalued growth stocks

Undervalued growth stocks

Discover the top 20 best undervalued large-cap growth stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.

3M Return 35.3%
S&P Outperformance 22.3%
Next 3M Predicted Return 26.8%
Undervalued dividend stocks

Undervalued dividend stocks

Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.

3M Return 28.4%
S&P Outperformance 15.4%
Next 3M Predicted Return 16.9%
More ideas -->

FAQ

1) What is Silence Therapeutics plc's Rule of 40 (EBIT margin)?

As of today, Microsoft Corp's last 12-month Rule of 40 (EBIT margin) is (401.0%), based on the financial report for Sep 30, 2024 (Q3’2024). The average annual Rule of 40 (EBIT margin) for Silence Therapeutics plc have been (171.7%) over the past three years, and (66.8%) over the past five years.

2) Is Silence Therapeutics plc's Rule of 40 (EBIT margin) Good?

As of today, Silence Therapeutics plc's Rule of 40 (EBIT margin) is (401.0%), which is lower than industry median of (288.7%). It indicates that Silence Therapeutics plc's Rule of 40 (EBIT margin) is Bad.

3) How does Silence Therapeutics plc's Rule of 40 (EBIT margin) compare to its peers?

As of today, Silence Therapeutics plc's Rule of 40 (EBIT margin) is (401.0%), which is lower than peer median of 20.2%. The list of peers includes ARGX, UTHR, NVO, REGN, BGNE, INCY, ALNY, VRTX, BNTX, SMMT.